Literature DB >> 15672859

High plasma concentrations of osteopontin in patients with interstitial pneumonia.

J Kadota1, S Mizunoe, K Mito, H Mukae, S Yoshioka, K Kawakami, Y Koguchi, K Fukushima, S Kon, S Kohno, A Saito, T Uede, M Nasu.   

Abstract

Osteopontin (OPN) produced by alveolar macrophages functions as a fibrogenic cytokine in the development of bleomycin (BLM)-induced murine pulmonary fibrosis, and OPN mRNA is expressed on lung tissues from patients with idiopathic pulmonary fibrosis (IPF). The present study investigates plasma OPN levels in human interstitial pneumonia (IP) and their relationships with disease severity by analyzing the correlation between plasma OPN concentrations and pulmonary functions. The concentrations of OPN in plasma were measured in 17 patients with IP, in 9 with sarcoidosis and in 20 healthy controls using an antigen-capture enzyme-linked immunosorbent assay. The concentrations of OPN in plasma were significantly higher in IP patients than in those with sarcoidosis or in controls. Based on a Receiver Operating Characteristic curve analysis, cut-off points between 300 and 380 ng/ml discriminated between IP and control subjects with 100% sensitivity and 100% specificity. In such case, the sensitivity for sarcoidosis decreased (55.5-33.3%) in cut-offs with 100% specificity. Plasma OPN levels inversely and closely correlated with arterial oxygen tension (PaO2) in patients with IP. Immunohistochemically, OPN was localized predominantly in macrophages and airway epithelium. These findings suggest that plasma OPN levels were found to be associated with the presence of IP, and that OPN play an important role in the development of IP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15672859     DOI: 10.1016/j.rmed.2004.04.018

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  24 in total

Review 1.  Gene expression profiling as a window into idiopathic pulmonary fibrosis pathogenesis: can we identify the right target genes?

Authors:  Naftali Kaminski; Ivan O Rosas
Journal:  Proc Am Thorac Soc       Date:  2006-06

Review 2.  Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways.

Authors:  Christopher M Evans; Tasha E Fingerlin; Marvin I Schwarz; David Lynch; Jonathan Kurche; Laura Warg; Ivana V Yang; David A Schwartz
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

3.  Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.

Authors:  Ann Chen Wu; James P Kiley; Patricia J Noel; Shashi Amur; Esteban G Burchard; John P Clancy; Joshua Galanter; Maki Inada; Tiffanie K Jones; Jonathan A Kropski; James E Loyd; Lawrence M Nogee; Benjamin A Raby; Angela J Rogers; David A Schwartz; Don D Sin; Avrum Spira; Scott T Weiss; Lisa R Young; Blanca E Himes
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

Review 4.  Peripheral blood biomarkers in idiopathic pulmonary fibrosis.

Authors:  Rekha Vij; Imre Noth
Journal:  Transl Res       Date:  2012-02-02       Impact factor: 7.012

Review 5.  Molecular biomarkers in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Kevin K Brown; Harold R Collard
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-09-26       Impact factor: 5.464

6.  Mesothelioma - Update on Diagnostic Strategies.

Authors:  Carmen M Rosario; Xiaoqi Lin; David W Kamp
Journal:  Clin Pulm Med       Date:  2012-11

Review 7.  Regulation of T-helper-cell lineage development by osteopontin: the inside story.

Authors:  Harvey Cantor; Mari L Shinohara
Journal:  Nat Rev Immunol       Date:  2009-02       Impact factor: 53.106

8.  Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF).

Authors:  Kathy Boon; Nathaniel W Bailey; Jun Yang; Mark P Steel; Steve Groshong; Dolly Kervitsky; Kevin K Brown; Marvin I Schwarz; David A Schwartz
Journal:  PLoS One       Date:  2009-04-06       Impact factor: 3.240

Review 9.  Molecular biomarkers in interstitial lung diseases.

Authors:  Angelo De Lauretis; Elisabetta A Renzoni
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

Review 10.  Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions.

Authors:  Anna Stainer; Paola Faverio; Sara Busnelli; Martina Catalano; Matteo Della Zoppa; Almerico Marruchella; Alberto Pesci; Fabrizio Luppi
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.